Avid Bioservices Inc (CDMO)

[biopharm]

Cheynew, I noticed Bernard Fox on the list of speakers as well.... with Bruce Freimark... and many others but hmmm, I couldn't find Avid or Peregrine listed under the floorplan or maybe they will be another company by that time.

http://www.triconference.com/Speakers/

... I noticed the very last speaker listed, appears to have no name attached..

Prof, Bioengineering, Pennsylvania State Univ

could that be the Director of experimental therapeutics - Dr. Peter O'Dwyer ? I am not positive yet

--------------------------------------------------------

Another one of interest re: AZ is Tom Plasterer

Director, US Cross-Science
AstraZeneca
March 2014 – Present (2 years 9 months)Greater Boston Area

In this role I manage a team of data scientists, developers and project managers deployed across a myriad of drug development projects, from target discover through real world evidence. I'm also continuing to advance linked data approaches inside and outside of BioPharma.

https://www.linkedin.com/in/tplasterer

---------------------------------------------------------

"We are very pleased with the performance of the Opal assay, particularly its ability to compare the interaction of up to 6 phenotypic and functional markers on a single slide of tissue. The power and prognostic value of such immune activity assessments in the area of cancer was initially established by the Immunoscore [ http://www.immunoscore.org ], and we believe the Opal assay represents an important evolution of that work," said Bernard A. Fox, Ph.D., Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Providence Cancer Center; a world-renowned translational cancer immunotherapist; a founding member of the Immunoscore steering committee [ http://www.ohsu.edu/xd/education/schools/school-of-medicine/academic-programs/graduate-studies/faculty/grad-studies-faculty.cfm?facultyid=104 ]. "I am looking forward to continued collaboration with Peregrine to further optimize and validate this assay to improve our understanding of immune infiltrate in tumors thereby facilitating the rational design and use of bavituximab in combination with novel and standard therapies."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118351795